Yang Ya-Zhi, Zhang Xiao-Yan, Wan Qian, Li Jian
Key Laboratory of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province,China; Medical Department of Nanchang University Graduate School, Nanchang 330006, Jiangxi Province,China.
Key Laboratory of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province,China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):301-305. doi: 10.7534/j.issn.1009-2137.2017.01.055.
Multiple myeloma (MM)is a kind of plasma tumor originated from B cell line. Its incidence ranks in second place of hematopoietic malignancies. Although continued progress was made in treatment of MM,the survival rate and prognosis of MM patients are still not satisfactory. Further understanding of the pathogenesis of MM may provide information to develop new treatment strategies, so as to improve survival rate and ameliorate its prognosis. Many researches have demonstrated that bone marrow microenvironment plays an important role in MM pathogenesis, which regulates the biological properties of MM cells, including migration and proliferation, through miRNA, mRNA and protein contained in the exosomes released from the cells in the tumor microenvironment. Recently, as the tumor suppressor genes and oncogenes, exosomal microRNA become a hot spot in research. Compared with those of the normal ones, exosomes in MM have less miR-15a and/or more miR-135b and miR-21. These differences will accelerate the progression of MM via PI3K/Akt/eNOS/VEGF pathway, FIH-HIF pathway, MAPK/ERK/Ras pathway and so on, that are expected to become the new targets for the treatment of MM. This review summarizes the role and the possible mechanism of exosomes in the progression of MM.
多发性骨髓瘤(MM)是一种起源于B细胞系的浆细胞肿瘤。其发病率在造血系统恶性肿瘤中位居第二。尽管MM的治疗取得了持续进展,但MM患者的生存率和预后仍不尽人意。进一步了解MM的发病机制可能为开发新的治疗策略提供信息,从而提高生存率并改善其预后。许多研究表明,骨髓微环境在MM发病机制中起重要作用,它通过肿瘤微环境中细胞释放的外泌体所含的miRNA、mRNA和蛋白质来调节MM细胞的生物学特性,包括迁移和增殖。近年来,作为肿瘤抑制基因和癌基因,外泌体微小RNA成为研究热点。与正常外泌体相比,MM中的外泌体miR-15a含量较少和/或miR-135b和miR-21含量较多。这些差异将通过PI3K/Akt/eNOS/VEGF途径、FIH-HIF途径、MAPK/ERK/Ras途径等加速MM的进展,有望成为MM治疗的新靶点。本文综述了外泌体在MM进展中的作用及可能机制。